T. Rowe Price Associates
UPB

T. Rowe Price Associates’s Upstream Bio Inc UPB Stock Holding History

T. Rowe Price Associates’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$238K Buy
26,434
+6,798
+35% +$122K ﹤0.01% 2773
2025
Q4 		$534K Buy
19,636
+1,135
+6% +$28.3K ﹤0.01% 2368
2025
Q3 		$349K Buy
18,501
+1,053
+6% +$16.4K ﹤0.01% 2529
2025
Q2 		$192K Buy
+17,448
New +$161K ﹤0.01% 2729

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's UPB Position: Q1 2026 in Review

T. Rowe Price Associates increased its Upstream Bio Inc (UPB) stake by 35% in Q1 2026, buying an estimated $122K and bringing the position to 26,434 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

T. Rowe Price Associates first reported a position in UPB in Q2 2025 and has held it in 4 quarters since. The position peaked at $534K in Q4 2025. 140 funds tracked by Wall St. Rank hold UPB as of Q1 2026.

  • T. Rowe Price Associates held 26,434 shares of Upstream Bio Inc worth $238K as of Q1 2026.
  • T. Rowe Price Associates bought 6,798 Upstream Bio Inc shares in Q1 2026, an estimated $122K.
  • Upstream Bio Inc made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2773 holding.
  • T. Rowe Price Associates first reported a position in Upstream Bio Inc in Q2 2025 and has held it in 4 quarters since.
  • T. Rowe Price Associates's Upstream Bio Inc position peaked at $534K in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.